Day One Biopharmaceuticals Total Current Liabilities

Day One Biopharmaceuticals (DAWN) currently reports a total current liabilities of $61M as of December 2025. That compares with $73M in the prior-year period — down 17.6% year over year. Use the charts on this page to explore Day One Biopharmaceuticals's total current liabilities history and peer comparisons.

Day One Biopharmaceuticals's total current liabilities decreased from $73M to $61M — a 17.6% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Day One Biopharmaceuticals reported $61M in total current liabilities as of December 2025. That compares with $73M in the prior-year period — down 17.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $61M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Day One Biopharmaceuticals, and consider following DAWN for alerts when major investors trade the stock.

Day One Biopharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $61M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DAWN with unrelated industries.